The ATP-binding cassette A1 (ABCA1) transporter plays a major role in the efflux of lipids by mediating the cellular transport of phospholipids and cholesterol to lipid-poor/lipid-free apolipoprotein A-I (apoA-I) particles and thereby exerting important anti-atherogenic effects. Although the mechanism whereby ABCA1 mediates cholesterol efflux is not completely understood, numerous studies have shown that, in addition to apoA-I, the expression level of the total or cell surface ABCA1 protein is a determining factor for the activity of ABCA1-mediated cholesterol efflux, and defects in ABCA1-mediated cholesterol efflux lead to various pathological conditions in different cells, including cardiovascular and metabolic disorders. It has been widely demonstrated that a growing list of natural and synthetic substances and metabolic regulators that modulate the expression of ABCA1 not only act directly on the ABCA1 gene promoter, but also occurs at the post-transcriptional level via micro-RNAs and post-translationally through the stabilization or localization of the protein. The complex regulatory network of ABCA1 results in promoting or suppressing cholesterol efflux from cells, therefore we speculate that the ABCA1 transporter is emerging as a novel therapeutic target for cardiovascular and metabolic disorders. Thus, ABCA1 is a key modulator of cellular cholesterol efflux and contributes to functional disorders in different types of cells.
INTRODUCTION
Studies indicate that the cholesterol efflux capacity of cells is strongly inversely associated with atherosclerosis [1] . The ATP-binding cassette A1 (ABCA1) transporter plays a major role in the efflux of lipids by targeting the free cholesterol(FC) and phospholipids(PLs) from macrophages and other cell types to lipid-poor/lipid-free apoA-I, the principal protein of HDL, to remove cellular lipids and generate HDL particles [2] . However, the mechanism of ABCA1-mediated cellular lipid efflux is unresolved. A two-step mechanism has been proposed that involves ABCA1 actively pumping phospholipids across the membrane to apoA-I to generate phospholipid-apoA-I complexes, which then promote cholesterol efflux in an autocrine or paracrine fashion [2, 3] . Other researchers indicate that the direct binding of apoA-I to ABCA1 located in the plasma membrane enhances the translocation of membrane phospholipids from the cytoplasmic to the exofacial leaflet. This phospholipid translocation then causes bending of the membrane bilayer, the formation of an exovesiculated domain to which apoA-I can bind with high affinity and the solubilization of membrane phospholipid and cholesterol to create nascent HDL particles [4] . Additionally, another study reported that the lysine residues in the extracellular domains of ABCA1 are required for the interaction with apoA-I leading to HDL formation [5] .
Studies have indicated that the concentration of apoA-I with amphipathic helices in the extracellular fluid is relevant *Address correspondence to this author at the No. 107 .Yanjiang West Road, Guangzhou, China, 510120; Tel: +86-13711675897; Fax:+86-020-81332360; E-mail: zzhangyuling@aliyun.com for determining the level of ABCA1 efflux [6] . However, except for hepatocytes and intestinal cells, most cells are unable to synthesize apoA-I. Moreover, the presence of apoA-I can also regulate the stability and localization of ABCA1 [7] , and ABCA1 can stabilize apoA-I by preventing the rapid degradation of apoA-I [8] . Therefore, the regulation of ABCA1 expression has been extensively studied regarding the modulation of cholesterol efflux and is considered to be a promising therapeutic target. Herein, we summarize recent studies that have provided insights into ABCA1 regulation, including at the levels of transcription, posttranscription and post-translation, and the various roles of ABCA1-mediated cholesterol efflux in variant cells.
TRANSCRIPTIONAL REGULATION OF ABCA1 EX-PRESSION
The ABCA1 gene is highly regulated transcriptionally. Metabolites, including sterols, retinoids, cAMP, and inflammatory factors, as well as drugs and active components from plants have been found to enhance or inhibit the activities of transcription factors that bind to the ABCA1 promoter and thereby modulate the transcription of ABCA1 and, in turn, alter cholesterol efflux activity.
Lipids, including sterols, retinoids, cholesterols, unsaturated fatty acids and modified LDLs, have been characterized as effective transcriptional modulators of sterolsensitive ABCA1 via LXRs among different cell types and species. Oxysterols, cis-retinoic acid (CRA) and LDL not only stimulate the binding of LXR/RXR heterodimers to the DR4 sequence in the ABCA1 promoter, but they also increase the PI3K/PKC pathway-dependent phosphorylation of Sp1, which binds to the proximal ABCA1 promoter, which is adjacent to the LXR/RXR responsive element, to facilitate transcription and thereby enhance cholesterol efflux in macrophages [9] [10] [11] . Sp1 can promote the recruitment of the LXR/RXR heterodimer to the ABCA1 promoter [10] , and a double mutation of the Sp1 and LXR binding sites almost completely blocks LDL-induced ABCA1 promoter activity; therefore, it has been suggested that the coordinate function of Sp1 and the LXR/RXR heterodimer is responsible for a full induction of ABCA1 expression. However, studies also indicate that oxidized LDL (oxLDL) promotes apoA-I-mediated cholesterol efflux from macrophages by upregulating ABCA1 transcription via enhancement of the binding of PPAR /LXR to the ABCA1 promoter [12] . Cellular cholesterol regulates ABCA1 expression differentially depending on the cell type. Cholesterol is a strong modulator of ABCA1 mRNA in fibroblasts, but not necessarily in HepG2 cells or monocyte-derived macrophages. Furthermore, the conversion of cholesterol to hydroxycholesterol, which targets the interaction of LXR/RXR and the DR4 sequence in the ABCA1 promoter, is required for cholesterolinduced transcription in fibroblasts [13] . In contrast, the sulfation of 25-hydroxycholesterol by SULT2B1b decreases the mRNA and protein levels of ABCA1 via the LXR/SREBP1c signaling pathway in HAECs [14] . Unsaturated fatty acids suppress ABCA1 gene transcription and cholesterol efflux to apoA-I through the LXR/RXR-DR4 pathway in macrophages [15] , but other studies indicate that unsaturated fatty acids also regulate ABCA1 expression post-translationally in other types of cells as described below.
cAMP also plays an important role in the regulation of ABCA1 gene expression. 8-Br-cAMP dramatically increases ABCA1 transcription in J774 mouse peritoneal macrophages, murine monocytes (P388) and neuroblastoma cells (N2A) dependent on the activation of the MAP-kinase pathway [16] and in the rat SMC line CRL-2018 dependent on the prolactin regulatory element-binding (PREB) protein [17] . Another study indicates that 8-Br-cAMP increases ABCA1 phosphorylation post-translationally via a cAMP/ PKA-dependent pathway, without any changes in the ABCA1 mRNA or protein levels, to promote apoA-I-mediated cellular lipid efflux [18] .
Atherosclerosis is characterized by a chronic inflammatory condition, and ABCA1 has been shown to be a possible link between inflammation and reverse cholesterol transport [19] . Proatherogenic cytokines, such as interferon (IFN)-gamma and IL-1beta, have been shown to transcriptionally inhibit the expression of ABCA1 by inhibiting LXR through a Jak/Stat-and NF-B-dependent mechanism and facilitate foam cell formation [20, 21] . However, antiatherogenic cytokines, including IL-6 IL-10 and transforming growth factor (TGF)-1, have been shown to promote the expression of ABCA1 and enhance cholesterol efflux to apoA-I by activating the Jak-2/Stat3, PPAR /LXRs, and LXR signaling pathways in macrophages [22] [23] [24] . Moreover, some cytokines, such as tumor necrosis factor (TNF)-alpha and lipopolysaccharide (LPS), seem to regulate ABCA1 expression in species-specific and dose-dependent manners. TNF-inhibits the expression of ABCA1 dependent on the PPAR /LXR pathway in HepG2 cells and the NF-B pathway in Caco-2 cells and macrophages and, thus, attenuates cholesterol efflux to apoA-I [25] [26] [27] . However, the expression of ABCA1 and cholesterol efflux is enhanced with low concentrations of TNF-alpha (5-10 ng/ml) through the PPAR /LXR pathway in adipocytes, while high concentrations of TNF-(20 ng/ml) have the opposite effect [28] . Furthermore, a study indicates that IL-18 and IL-12 together, which increase IFN-secretion, can decrease ABCA1 expression and cellular cholesterol efflux in THP-1 macrophage-derived foam cells by increasing the level of ZNF202 [29] , an ABCA1 transcriptional repressor that acts via binding to an ABCA1 promoter GC-box and an Ets-binding motif [30] . The inflammation induced by LPS has been found to block the expression of ABCA1 via NF-B in RAW 264.7 cells [31] , while an increased expression of ABCA1 induced by LPS via the activation of p38 MAP kinase has been observed in THP-1 monocytes [32] . However, a recent study indicates that LPS reduces the level of only the ABCG1 and SR-BI proteins, but not ABCA1 in murine macrophages [33] . These results suggest a new role of ABCA1 linking inflammatory cytokines and atherogenesis.
Some drugs and active components from plants have been demonstrated to be anti-atherosclerotic by increasing ABCA1 transcription and thereby promoting RCT. Niacin, the most effective agent clinically available to raise HDL, increases apoA-I lipidation by enhancing lipid efflux through the LXR /DR4-dependent transcription of ABCA1 in HepG2 cells [34] . In addition, agonists of peroxisome proliferator activated receptors (PPARs), which lack a corresponding response element in the ABCA1 promoter, including pioglitazone, fibrates and astaxanthin, can upregulate ABCA1 gene expression dependent on or independent of the PPARs/LXR pathway for activating ABCA1 transcription [35] [36] [37] [38] . Statins also induce the accumulation of ABCA1 mRNA dependent on PPARs/LXR . Nevertheless, some studies indicate that PPAR activates ABCA1 gene transcription but reduces the level of ABCA1 protein in HepG2 cells [39] . Pitavastatin increases ABCA1 expression by a mechanism involving sterol-responsive element-binding protein 2 (SREBP2)-dependent transcriptional activation without activating LXR in rat hepatoma cells [40] , while SREBP2 has been shown to increase ABCA1 gene expression via an LXR/DR4-related mechanism in CHO cell lines [41] . However, other studies indicate that SREBP2 downregulates the level of ABCA1 mRNA via binding to an ABCA1 promoter E-box motif, a site known to negatively regulate ABCA1 transcription, in vascular endothelial cells [42] . The differential regulation of ABCA1 transcription by SREBP2 may result from the different cell types involved. Angiotensin II treatment reduced the ABCA1 promoter activity by inducing the binding of fos-related antigen 2 (Fra2) protein to an ABCA1 promoter E-box motif, and the Ang II type 1 receptor blocker valsartan inhibited Ang II-induced ABCA1 mRNA repression [43] . Similarly to E-box, AP2 is also a negative regulator of the ABCA1 promoter; studies indicate that doxazosin can upregulate ABCA1 expression through the PKD-mediated phosphorylation of Ser258 of the activator protein (AP)2 , which results in the decreased binding of AP2 to the ABCA1 promoter and increased ABCA1 transcription [44, 45] . In addition, it has also been shown that ethanolic extracts of the Brazilian red propolis (EERP) [46] and hesperetin, a citrus flavonoid [47] promote apoA-Imediated cholesterol efflux from macrophages by upregulating ABCA1 transcription via enhancing PPAR /LXR binding to the ABCA1 promoter. Quercetin, another flavonoid, enhances TAK1-MKK3/6-p38-mediated binding of Sp1 and LXR to their corresponding binding sites in the ABCA1 promoter to increase ABCA1 expression and cholesterol efflux from macrophages [48] .
POST-TRANSCRIPTIONAL REGULATION OF ABCA1 EXPRESSION
The ABCA1 protein level does not always correlate with the level of ABCA1 mRNA, which suggests the presence of post-transcriptional regulation [49] . MicroRNAs (miRNAs) have emerged as important post-transcriptional regulators of lipid metabolism. miRNAs have been found to downregulate their target genes post-transcriptionally by binding to mRNA sequences typically located in the 3 untranslated regions (3 UTRs), causing translational inhibition or mRNA cleavage [50] .
MicroRNA-33a and b (miR-33a/b), within intronic sequences of the sterol response element-binding protein (SREBP) genes Srebp2 and Srebp1, are negative modulators of ABCA1 expression in hepatocytes and macrophages. Further experiments show that the effects of miR-33a/b are mediated through binding to the functional miR-33-responsive element in the ABCA1 3 UTR (nucleotides 120-172 downstream of the stop codon), leading to the repression of translation or post-transcriptional mRNA degradation [51, 52] . The overexpression of miR-33 via transfection with synthetic miR-33 precursor oligonucleotides has been shown to inhibit the expression of ABCA1 in J774 cells, HepG2 hepatoma cells, or IMR-90 fibroblasts, while silencing miR-33 with antisense oligonucleotides results in increased levels of ABCA1 and in increased cholesterol efflux from J774 cells. There are higher ABCA1 protein levels in the liver and significantly higher serum HDL cholesterol levels in miR-33-deficient mice than in WT mice [53] . Other miRNAs, such as miR-758 and miR-26, an LXR-suppressed miRNA, have been shown to post-transcriptionally down-regulate ABCA1 levels in different cells and suppress macrophage cellular cholesterol efflux to apoA-I [54, 55] . Thus, oligonucleotide inhibitors of miRNAs may promote the reverse cholesterol transport pathway in two ways: by directly increasing HDL biogenesis in the liver and by increasing cellular cholesterol efflux from macrophages [56] .
MicroRNAs may also be involved in other pathological conditions that result from the suppression of ABCA1 expression. Studies indicate that adenoviral miR-33a overexpression in both human and mouse islets results in decreased pancreatic islet ABCA1 expression. This reduced ABCA1 expression then leads to cholesterol accumulation and defective -cell function, including reduced glucose-stimulated insulin secretion (GSIS) [57] , which establishes an association between defective ABCA1 and T 2 DM. In another study, miR-106b was found to impair cellular cholesterol efflux by suppressing ABCA1 expression in neuronal cells, and miR106b also increased the levels of secreted amyloid , which triggers the pathogenic cascades leading to Alzheimer's disease (AD) [58] . However, some studies have shown that other miRNAs, including miR-122 and miR-370, cannot regulate the expression of ABCA1 [59] . Nevertheless, miRNA antagonists might be a possible target for the treatment of cardiovascular and metabolic disorders [60, 61] .
POST-TRANSLATIONAL REGULATION OF ABCA1 EXPRESSION
The ABCA1 transporter resides on the cell surface and in intracellular compartments, including early endosomes and late endosomes/lysosomes that are utilized for ABCA1 degradation or recycling to the plasma membrane, and studies have indicated that ABCA1 functions in lipid efflux and HDL biogenesis at the cell surface rather than in the intracellular compartments [62, 63] . Alterations in ABCA1 cell surface expression change the cholesterol efflux activity. The post-translational regulation of ABCA1 to influence the cell surface expression of ABCA1 plays an important role in the efflux of cellular lipids. Studies show that the stability and cell surface expression of ABCA1 can be regulated through degradation by calpain proteolysis or by the ubiquitin proteasome system (UPS) [64, 65] and the rapid trafficking of ABCA1 between the cell membrane and intracellular vesicles [63] by post-translational mechanisms.
With a half-life of 1-2 h [66] , a decreased rate of clearance for ABCA1 is vital for ABCA1 to recycle to the plasma membrane surface, and the rapid clearance of ABCA1 is specifically inhibited by a calpain inhibitor [64, 67] . Therefore, calpain-mediated proteolytic degradation, as one of the post-translational regulatory mechanisms, plays a vital role in regulating the activity of ABCA1. The degradation takes place in the early endosomes after ABCA1 is internalized, and calpain apparently cleaves ABCA1 at the PEST sequence in the cytosolic loop in the middle of the molecule [67] . Deletion of the PEST sequence leads to a decrease in the internalization of ABCA1 and results in a prominent increase in the cell surface concentration of ABCA1 and decreased cholesterol efflux from late endosomal cholesterol pools in HEK293 cells [68] .
Many substances regulate the stability and localization of ABCA1 by inhibiting or enhancing calpain-mediated proteolytic degradation. Extracellular apolipoprotein A-I has been shown to stabilize ABCA1 against the degradation by calpain and to recycle ABCA1 to the surface [62] ; these effects then result in the increased generation of HDL by the interaction between ABCA1 and phospholipase C (PL-C ) [69] .
1-syntrophin acts through a class-I PDZ interaction with the C terminus of ABCA1 to enhance ABCA1 cholesterol efflux by stabilizing newly translated ABCA1 protein and facilitating its expression at the cell surface [70] . Meanwhile, spiroquinone and diphenoquinone, two oxidized products of probucol, have been shown to cause the retardation of ABCA1 degradation by inhibiting the internalization of ABCA1, a prerequisite for calpain-mediated proteolysis, and thereby enhance the generation of HDL [65] . In contrast, unsaturated free fatty acids, eicosapentaenoic acid (EPA) and the ApoA-I mimetic peptide D4-F have been found to result in the phos-phorylation of ABCA1 serines by activating the phospholipase D (PLD)/PKC [71] [72] [73] , cAMP/PKA [74] and Cdc42/ cAMP/PKA [75] signaling pathway, respectively, to stabilize ABCA1 against proteolysis. In contrast, wogonin increases the stability of ABCA1 via protein phosphatase 2B-mediated dephosphorylation and enhances cholesterol efflux in macrophage foam cells [76] .
The ubiquitin proteasome system (UPS), containing ubiquitin-activating enzyme (E1), ubiquitin-conjugating enzymes (E2s), ubiquitin-ligases (E3s) and the 26S proteasome, constitutes a major non-lysosomal pathway for the intracellular degradation of proteins, and ABCA1 has recently been reported to undergo protein degradation via the UPS. The COP9 signalosome (CSN) complex, a key molecule involved in controlling protein ubiquitination and deubiquitination, decreases ubiquitinated ABCA1 and consequently inhibits the proteasomal degradation of ABCA1 in HEK293 cells [77] . The HIV-1 Nef protein expressed in HEK293 cells strongly inhibited ABCA1 efflux and protein levels through the acceleration of ABCA1 protein degradation dependent on proteasomal function but not the ABCA1 PEST sequence, which mediates the calpain proteolysis of ABCA1. This provides evidence for a potentially proatherosclerotic effect of Nef [78] . Free cholesterol preloading in macrophages leads to decreased levels of the ABCA1 protein and defective ABCA1-mediated cholesterol efflux not by the decreased transcription or translation of ABCA1 mRNA but via the increased proteasomal degradation of ABCA1; furthermore, the inhibition of proteasomal function by lactacystin largely prevented the degradation of ABCA1 [79] . Recent studies have also shown the positive effects of proteasome inhibitors in promoting RCT both in vivo and in vitro via the inhibition of ABCA1 protein degradation [64] . Therefore, specific inhibition of the UPS pathway might lead to a novel therapeutic strategy for atherosclerotic diseases.
The complex intracellular trafficking of ABCA1 between the cell surface and intracellular vesicles plays an important role in modulating ABCA1 activity and the efficient efflux of cellular lipids to apoA-I. Treatment with brefeldin A, an inhibitor of trans-Golgi transport, can block the delivery of newly synthesized ABCA1 to the cell surface and then inhibit the ABCA1-induced cellular sterol efflux [80] . One subunit of the serine palmitoyltransferase enzyme, SPTLC1, blocks the trafficking of ABCA1 out of the endoplasmic reticulum and onto the cell surface, and the pharmacologic inhibition of SPTLC1 with myriocin increases cholesterol efflux by 50% and the level of cell surface ABCA1 by 30% [81] . Additionally, cathepsin D (CTSD), a lysosomal protease involved in the degradation of proteins in the lysosome/ late endosome compartment, has been shown to promote the trafficking of ABCA1 to the cell surface. Treatment with ceramide produced by acid sphingomyelinase increases the level of cell surface ABCA1 and cholesterol efflux by directly binding to and activating CTSD [82] . In contrast, the inhibition of CTSD by pepstatin causes the retention of ABCA1 in lysosomal compartments, impairing its trafficking to the plasma membrane [83] . A study on low-density lipoprotein receptor-related protein-1 (LRP1) deficient mice revealed a decreased hepatocyte surface localization of ABCA1, without changes in the total cellular ABCA1 level, due to a reduction in CTSD activity and thus resulting in a reduced formation of plasma HDL [84] .
THE ROLE OF ABCA1-MEDIATED CHOLESTEROL EFFLUX IN VARIANT CELLS
It has been established that ABCA1 plays a major role in cholesterol efflux, and genetic loss-of-function mutations in the ABCA1 transporter lead to Tangier disease (TD), which is characterized by severe HDL deficiency, rapid apoA-I clearance, massive sterol deposition in macrophage-enriched tissues and premature atherosclerotic vascular disease [85] . However, the role of ABCA1-mediated cholesterol efflux appears to vary in different cells, including hepatic and extrahepatic cells, and this role is likely to be relevant to the potential pathological conditions. Plasma high-density lipoprotein (HDL) levels bear a strong independent inverse relationship with atherosclerotic cardiovascular disease [86] , and hepatocytes play pivotal roles in plasma HDL formation through the ABCA1 transporter. Plasma HDL is generated in the liver and intestine dependent on the activity of ABCA1. The cell-specific deletion of ABCA1 demonstrates that hepatocytes are the predominant cell type responsible for HDL formation in vivo, contributing 70-80% of the plasma HDL pool, whereas the intestine contributes 20-30% [87] . However, recent studies using adipocyte-specific ABCA1 knockout mice illustrate that deletion of adipocyte ABCA1 also results in a significant decrease in plasma HDL cholesterol to approximately 15% [88] . Studies using hepatocyte-specific knockout (HSKO) mice indicate that ABCA1 in hepatocytes is essential for cholesterol efflux to apoA-I and nascent HDL formation, to which ABCG1 and SR-BI in hepatocytes make no contribution [89] . The ABCA1-mediated lipidation of apoA-I that largely occurs at the plasma membrane is important for generating nascent HDL [90, 91] . Because HDL biogenesis contributes significantly to the antiatherogenic process of RCT, this mechanism of apoA-I lipidation is critical to cellular cholesterol homeostasis, especially in macrophages. Therefore, hepatic ABCA1 deficiency has been shown to be related to metabolic syndrome (MS) through influencing lipid metabolism. Studies silencing ABCA1 in rat hepatoma cells or using hepatocyte-specific ABCA1 knockout (HSKO) mice indicate an absence of large nascent HDL, which in turn leads to decreased PI3 kinase activation, increased lipid mobilization into maturing VLDL particles, and the secretion of larger TG-enriched VLDL particles [92] . ABCA1 in hepatocytes is critical for nascent HDL formation and lipid metabolism.
In contrast to hepatic ABCA1, which generates major nascent HDL particles, extrahepatic ABCA1 is responsible for removing cellular cholesterol to form mature HDL particles. The dysfunction of ABCA1 in different cells may lead to various pathological changes. In macrophages, ABCA1 effluxes excess cholesterol to both apoA-I and pre-HDL particles to generate mature HDL, which is then delivered to the liver for excretion in the bile and feces, a process known as reverse cholesterol transport (RCT). A defective ABCA1 protein in macrophages leads to the early pathological changes of atherosclerosis, including the formation of foam cells and a fatty streak [93, 94] . ABCA1 is also associated with type 2 diabetes [95] . Mice with a -Cell-specific ABCA1 knockout or loss-of-function mutations in the ABCA1 gene exhibit impaired glucose tolerance, defective insulin secretion, and altered islet cholesterol homeostasis [96, 97] . Studies indicate that balsamic vinegar can improve the insulin secretion of beta-cells by increasing beta-cell ABCA1 expression [98] . In the central nervous system, ABCA1 mediates cholesterol and phospholipid efflux to facilitate the lipidation of apoE and influence brain apoE levels, the major apolipoprotein that modulates brain cholesterol homeostasis and plays a critical role in AD through directly interacting with excessive amyloid-(A ) [99, 100] . Therefore, ABCA1 has been proposed to play a potential role in AD pathology [101] . Studies indicate that the overexpression of ABCA1 via LXR activation can reduce A production and secretion both in AD mouse models and in vitro [102, 103] , while the LXR-deficiency-induced inhibition of ABCA1 or the knock-out of ABCA1 in mice results in reduced ApoE protein levels and increased levels of A in the brain compared with wild-type mice [104, 105] . However, a recent meta-analysis detected no significant association between ABCA1 polymorphisms and the risk for AD [106] . Moreover, ABCA1 deficiency in cancer cells results in increased mitochondrial cholesterol, inhibits the release of mitochondrial cell death-promoting molecules and thus facilitates cancer cell survival, which suggests that ABCA1 efflux has anti-cancer activity [107] . Studies indicate that the attenuated ABCA1 expression in androgen-independent cells may thus contribute to prostate cancer progression [108] , and lycopene inhibits prostate cancer cell proliferation via the induction of ABCA1 expression through the PPAR /LXR pathway [109] .
Niemann-Pick type C (NPC) disease [110] , a lysosomal cholesterol storage disorder [111] , results from mutations in either the NPC1 or NPC2 genes, which facilitate the transport of cholesterol from late endosomes/lysosomes to other compartments, including the endoplasmic reticulum (ER) and the plasma membrane. The cholesterol trafficking defect in NPC disease results in the reduced activity of ABCA1, leading to reduced HDL particle formation. Although genetic deletion of ABCA1 in the NPC1 mouse did not affect sterol balance [112] , increasing ABCA1 expression, either with an LXR agonist [113] or by infection with an adenovirus expressing the full-length ABCA1 gene [114] , in NPC1 -/-fibroblasts resulted in the normalization of cholesterol efflux to apoA-I and -HDL particle formation, plus a marked reduction in filipin staining of unesterified cholesterol in the late endosomes/lysosomes. These results suggest that the correction of ABCA1 expression can bypass the mutation of NPC1 and mobilize excess cholesterol from the late endosomes/lysosomes in NPC disease cells.
CONCLUSION
The main role of the ABCA1 transporter is to target FC and PLs efflux to lipid-free/lipid-poor apoA-I to remove cellular lipids and generate nascent HDL particles, both of which contribute to the antiatherogenic capacity of RCT. In addition, ABCA1 efflux contributes to the maintenance of normal cellular functions, and defects in ABCA1 efflux may contribute to the pathological changes in diabetes, AD, and even some cancers, while the overexpression of ABCA1 can correct the excessive cholesterol deposits in the late endosomes/lysosomes in NPC disease. Numerous substances, with pathogenic or antipathogenic properties, have been found to affect cellular cholesterol efflux through regulating ABCA1 expression at different levels, including interesting post-transcriptional and post-translational pathways. The complex regulatory network of ABCA1 may broaden our perspective on novel therapeutic strategies for cardiovascular and metabolic disorders.
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